Edwards Lifesciences Return on Tangible Equity 2010-2022 | EW

Current and historical return on tangible equity values for Edwards Lifesciences (EW) over the last 10 years. Return on tangible equity can be defined as the amount of net income returned as a percentage of shareholders equity, after subtracting intangible assets, goodwill and preferred equity.
Edwards Lifesciences Return On Tangible Equity Historical Data
Date TTM Net Income Tangible Equity Return on Tangible Equity
2022-09-30 $1.46B $4.79B 32.51%
2022-06-30 $1.46B $4.46B 33.83%
2022-03-31 $1.54B $4.36B 37.58%
2021-12-31 $1.50B $4.34B 39.60%
2021-09-30 $1.48B $4.05B 42.51%
2021-06-30 $1.46B $3.64B 46.56%
2021-03-31 $0.85B $3.16B 30.20%
2020-12-31 $0.82B $3.07B 31.34%
2020-09-30 $0.79B $2.71B 31.48%
2020-06-30 $0.74B $2.34B 30.81%
2020-03-31 $1.11B $2.40B 47.85%
2019-12-31 $1.05B $2.64B 47.24%
2019-09-30 $0.77B $2.28B 39.16%
2019-06-30 $0.73B $1.94B 39.19%
2019-03-31 $0.77B $2.00B 43.53%
2018-12-31 $0.72B $1.69B 43.45%
2018-09-30 $0.71B $1.77B 45.03%
2018-06-30 $0.66B $1.58B 41.52%
2018-03-31 $0.56B $1.62B 35.47%
2017-12-31 $0.58B $1.36B 38.29%
2017-09-30 $0.75B $1.77B 45.73%
2017-06-30 $0.72B $1.57B 43.37%
2017-03-31 $0.66B $1.40B 39.39%
2016-12-31 $0.57B $1.79B 33.82%
2016-09-30 $0.55B $1.86B 33.34%
2016-06-30 $0.53B $1.63B 33.27%
2016-03-31 $0.52B $1.47B 31.09%
2015-12-31 $0.50B $1.67B 28.34%
2015-09-30 $0.46B $1.59B 26.05%
2015-06-30 $0.44B $1.90B 24.60%
2015-03-31 $0.87B $1.83B 51.74%
2014-12-31 $0.81B $1.79B 55.40%
2014-09-30 $0.78B $1.64B 59.88%
2014-06-30 $0.76B $1.50B 66.84%
2014-03-31 $0.31B $0.92B 29.22%
2013-12-31 $0.39B $1.13B 35.39%
2013-09-30 $0.40B $0.99B 37.50%
2013-06-30 $0.40B $1.13B 35.63%
2013-03-31 $0.37B $1.15B 34.23%
2012-12-31 $0.29B $1.03B 28.03%
2012-09-30 $0.27B $1.13B 26.20%
2012-06-30 $0.25B $1.02B 25.74%
2012-03-31 $0.24B $0.98B 25.10%
2011-12-31 $0.24B $0.92B 25.28%
2011-09-30 $0.24B $0.94B 25.46%
2011-06-30 $0.24B $0.96B 25.63%
2011-03-31 $0.24B $0.93B 27.38%
2010-12-31 $0.22B $0.93B 26.92%
2010-09-30 $0.20B $0.85B 26.20%
2010-06-30 $0.23B $0.73B 31.22%
2010-03-31 $0.22B $0.75B 31.27%
2009-12-31 $0.23B $0.76B 35.94%
Sector Industry Market Cap Revenue
Medical Medical Instruments Manufacturing $47.328B $5.233B
Edwards Lifesciences Corporation deals in products and technologies aimed at treating advanced cardiovascular diseases, especially structural heart disease in critically ill patients. The company is the world's leading manufacturer of tissue heart valves and repair products used to replace or repair a patient's diseased or defective heart valve. Edwards is also a leading player in hemodynamic monitoring systems used to measure a patient's cardiovascular function in the hospital setting. The company's products and technologies are categorized into four main areas: Transcatheter Aortic Valve Replacement (TAVR), Transcatheter Mitral and Tricuspid Therapies (TMTT), Surgical Structural Heart, and Critical Care.
Stock Name Country Market Cap PE Ratio
Thermo Fisher Scientific (TMO) United States $220.806B 23.09
Alcon (ALC) Switzerland $34.365B 29.59
STERIS (STE) Ireland $19.157B 23.84
Teleflex (TFX) United States $11.379B 18.46
Fresenius Medical Care AG KGaA (FMS) Germany $9.600B 9.64
Penumbra (PEN) United States $8.008B 1916.82
Globus Medical (GMED) United States $7.483B 38.05
Integer Holdings (ITGR) United States $2.426B 19.47
Glaukos (GKOS) United States $2.281B 0.00
Nevro (NVRO) United States $1.601B 0.00
Paragon 28 (FNA) United States $1.511B 0.00
AVANOS MEDICAL, INC (AVNS) United States $1.261B 17.96
Artivion (AORT) United States $0.546B 0.00